ПРОТИПУХЛИННІ КСЕНОГЕННІ ВАКЦИНИ НА ОСНОВІ АНТИГЕНІВ КУРКИ. ЧОМУ НІ?
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-23-1-2021-g.9368Ключові слова:
екстракт ембріона курки, карцинома Ерліха, карцинома легені Льюїс, ксеногенна протипухлинна вакцина, протипухлинна ефективність, протипухлинні імунологічні реакціїАнотація
Протипухлинні вакцини надалі привертають увагу вчених. З кожним роком публікується все більше статей, присвячених розробці вакцин проти раку. Вивчаються нові підходи для підвищення їх ефективності, включно з використанням ксеногенних аналогів антигенів. Мета: підсумувати основні результати, отримані в процесі створення ксеногенної протипухлинної вакцини на основі антигенів ембріона курки. Висновки: показано, що ЕДТА-екстракт ембріона курки містить щонайменше 2 гомологічні білки (ММР-2 та VEGF), виявляє протиракову активність на моделі карциноми легені Льюїс і раку Ерліха та активує імунні реакції, які беруть участь у протипухлинному захисті. Незважаючи на те, що досить багато аспектів ще потребують детального вивчення, екстракт ембріона курки може бути використаний для розробки ксеногенних протипухлинних вакцин.
Посилання
Wada S, Yada E, Ohtake J, et al. Current status and future prospects of peptide-based cancer vaccines. Immunotherapy 2016; 8 (11): 1321–3.
Cavallo F, Aurisicchio L, Mancini R, Ciliberto G. Xenogene vaccination in the therapy of cancer. Expert Opin Biol Ther 2014; 14 (10): 1427–42.
Fong L, Brockstedt D, Benike C, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001; 167 (12): 7150–6.
Luo Y, Wen Y-J, Ding Z-Y, et al. Іmmunotherapy of tumors with protein vaccine based on chicken homologous Tie-2. Clin Cancer Res 2006; 12 (6): 1813–9.
Ciesielski MJ, Apfel L, Barone TA, et al. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol Immunother 2006; 55 (12): 1491–503.
Zhu K, Qin H, Cha SC, et al. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine 2007; 25 (46): 7955–61.
Dyall R, Bowne WB, Weber LW, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998; 188 (9): 1553–61.
Gold JS, Ferrone CR, Guevara-Patiño JA, et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 2003; 170 (10): 5188–94.
Guevara-Patiño JA, Turk MJ, Wolchok JD, Houghton AN. Immunity to cancer through immune recognition of altered self: studies with melanoma. Adv Cancer Res 2003; 90: 157–77.
Tangri S, Ishioka GY, Huang X, et al. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 2001; 194 (6): 833–46.
Riccardo F, Bolli E, Macagno M, et al. Chimeric DNA vaccines: an effective way to overcome immune tolerance. Curr Top Microbiol Immunol 2017; 405: 99–122.
He QM, Wei YQ, Tian L, et al. Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice. J Biol Chem 2003; 278 (24): 21831–6.
Zhang W, Liu J, Wu Y, et al. Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice. Biochem Biophys Res Commun 2008; 376 (1): 10–4.
Fedosova NI, Voeykova IM, Karaman ОМ, et al. Cytotoxic activity of immune cells following administration of xenogeneic cancer vaccine in mice with melanoma B-16. Exp Oncol 2015; 37 (2): 130–4.
Yuan J, Ku GY, Gallardo HF, et al. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. accessed May 20, 2021 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888533/
Aurisicchio L, Roscilli G, Marra E, et al. Superior immunologic and therapeutic efficacy of a xenogeneic genetic cancer vaccine targeting carcinoembryonic human antigen. Hum Gene Ther 2015; 26 (6): 386–98.
Wei YQ, Wang QR, Zhao X, et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6: 1160–6.
Jiao JG, Li YN, Wang H, et al. A plasmid DNA vaccine encoding the extracellular domain of porcine endoglin induces anti-tumour immune response against self-endoglin-related angiogenesis in two liver cancer models. Dig Liver Dis 2006; 38 (8): 578–87.
Tan GH, Wei YQ, Tian L, et al. Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen. Eur J Immunol 2004; 34 (7): 2012–21.
Liu JY, Wei YQ, Yang L, et al. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 2003; 102 (5): 1815–23.
Su JM, Wei YQ, Tian L, et al. Active immunogene therapy of cancer with vaccine on the basis of chicken homologous matrix metalloproteinase-2. Cancer Res 2003; 63 (3): 600–7.
Lou YY, Wei YQ, Yang L, et al. Immunogene therapy of tumors with a vaccine based on the ligand-binding domain of chicken homologous integrin beta3. Immunol Invest 2002; 31 (1): 51–69.
Zheng S, Zhang J, Zheng S, et al. Anti-angiogeneic target therapy for cancer with vaccine based on the recombinant chicken FGFR-1 in tumor-bearing mice. J Huazhong Univ Sci Technolog Med Sci 2007; 27 (2): 120–3.
Yi T, Wei YQ, Tian L, et al. Humoral and cellular immunity induced by tumor cell vaccine based on the chicken xenogeneic homologous matrix metalloproteinase-2. Cancer Gene Ther 2007; 14 (2): 158–64.
Yu WY, Chuang TF, Guichard C, et al. Chicken HSP70 DNA vaccine inhibits tumor growth in a canine cancer model. Vaccine 2011; 29 (18): 3489–500.
Hahn-Dantona EA, Aimes RT, Quigley JP. The isolation, characterization, and molecular cloning of a 75-kDa gelatinase B-like enzyme, a member of the matrix metalloproteinase (MMP) family. An avian enzyme that is MMP-9-like in its cell expression pattern but diverges from mammalian gelatinase B in sequence and biochemical properties. J Biol Chem 2000; 275 (52): 40827–38.
Aimes RT, French DL, Quigley JP. Cloning of a 72 kDa matrix metalloproteinase (gelatinase) from chicken embryo fibroblasts using gene family PCR: expression of the gelatinase increases upon malignant transformation. Biochem J 1994; 300: 729–36.
Yamaguchi S, Iwata K, Shibuya M. Soluble. Flt-1 (soluble VEGFR-1), a potent natural antiangiogenic molecule in mammals, is phylogenetically conserved in avians. Biochem Biophys Res Commun 2002; 291 (3): 554–9.
Jones PF, McClain J, Robinson DM, et al. Identification and characterisation of chicken cDNAs encoding the endothelial cell-specific receptor tyrosine kinase Tie2 and its ligands, the angiopoietins. Angiogenesis 1998; 2 (4): 357–64.
Shibuya M. Vascular Endothelial Growth Factor Receptor Family genes: when did the three genes phylogenetically segregate? Biol Chem 2002; 383: 1573–9.
Yue Z, Carvalho A, Xu Z, et al. Deconstructing Survivin: comprehensive genetic analysis of Survivin function by conditional knockout in a vertebrate cell line. J Cell Biol 2008; 183 (2): 279–96.
Scavo LM, Serrano J, Roth J, de Pablo F. Genes for the insulin receptor and the insulin-like growth factor I receptor are expressed in the chicken embryo blastoderm and throughout organogenesis. Biochem Biophys Res Commun 1991; 176 (3): 1393–401.
Bassuk JA, Iruela-Arispe ML, Lane TF, et al. Molecular analysis of chicken embryo SPARC (osteonectin). Eur J Biochem 1993; 218: 117–27.
Schneider J, Linares R, Martínez-Arribas F, et al. Developing chick embryos express a protein which shares homology with the nuclear pore complex protein Nup88 present in human tumors. Int J Dev Biol 2004; 48 (4): 339–42.
López-Sánchez N, González-Fernández Z, Niinobe M, et al. Single mage gene in the chicken genome encodes CMage, a protein with functional similarities to mammalian type II Mage proteins. Physiol Genomics 2007; 30 (2): 156–71.
Zheng S, Huang F, Zheng S, et al. Vaccination with a recombinant chicken FGFR-1 bypasses immunological tolerance against self-FGFR-1 in mice. J Huazhong Univ Sci Technolog Med Sci 2006; 26 (4): 389–91.
Vermaelen K. Vaccine Strategies to improve anti-cancer cellular immune responses. Front Immunol 2019; 10: 8.
Brewer GB, Mitchell AR, Harandi A, Eaton JW. Embryonic vaccines against cancer: An early history. Experim Mol Pathol 2009; 86: 192–7.
Kim J, Woo AJ, Chu J, et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 2010; 143 (2): 313–24.
Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008; 40 (5): 499–507.
Kim WT, Ryu CJ. Cancer stem cell surface markers on normal stem cells. BMB Rep 2017; 50 (6): 285–98.
Isokawa K, Rezaee M, Wunsch A, et al. Identification of transferrin as one of multiple EDTA-extractable extracellular proteins involved in early chick heart morphogenesis. J Cell Biochem 1994; 54 (2): 207–18.
Mjaatvedt CH, Lepera RC, Markwald RR. Myocardial specificity for initiating endothelial-mesenchymal cell transition in embryonic chick heart correlates with a particulate distribution of fibronectin. Dev Biol 1987; 119 (1): 59–67.
Symchych TV. Anticancer and immuno-biologic properties of xenogeneic embryo proteins (experimental research). Manuscript. Thesis Candidate of Biol Sciences Degree; speciality 14.01.07. R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine. Kyiv, 2019. 222 p. (in Ukrainian).
Hawkes SP, Li H, Taniguchi GT. Zymography and reverse zymography for detecting MMPs and TIMPs. Methods Mol Biol 2010; 622: 257–269.
Chen JM, Aimes RT, Ward GR, et al. Isolation and characterization of a 70-kDa metalloprotease (Gelatinase) that is elevated in Rous Sarcoma Virus-transformed chicken embryo fibroblasts. J Biol Chem 1991; 266 (8): 5113–21.
Xu A, Zhang L, Chen Y, et al. Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models. Cancer Immunol Immunother 2017; 66 (2): 181–92.
Kamstock D, Elmslie R, Thamm D, Dow S. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother 2007; 56: 1299–309.
Morera-Díaz Y, Gavilondo JV, Bequet-Romero M, et al. Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside. Semin Oncol 2018; 45 (1–2): 68–74.
Kyutoku M, Nakagami H, Koriyama H, et al. Development of novel DNA vaccine for VEGF in murine cancer model. Sci Rep 2013; 3: 3380.
Wang B, Kaumaya PT, Cohn DE. Immunization with synthetic VEGF peptides in ovarian cancer. Gynecol Oncol 2010; 119 (3): 564–70.
Symchych TV, Karaman OM, Yudina OY, et al. Toxic and immunomodulating effects evaluation of chicken embryonic proteins on BALB/C mice. NaUKMA Research Papers. Biology and Ecology 2009; 93: 31–36. (in Ukrainian)
Watanabe H, Numata K, Ito T, et al. Innate immune response in Th1- and Th2-dominant mouse strains. SHOCK 2004; 22 (5): 460–6.
Symchych TV, Fedosova NI, Karaman OM, et al. The anticancer efficiency of the xenogeneic vaccine and the indication for its use. Exp Oncol 2014; 36 (2): 79–84.
Symchych TV, Fedosova NI, Karaman ОМ, et al. Anticancer effectiveness of vaccination based on xenogeneic embryo proteins applied in different schedules. Exp Oncol 2015; 37 (3): 197–202.
Symchych TV, Fedosova NI, Karaman ОМ, et al. Anticancer effect and immunologic response to xenogeneic embryonic proteins in mice bearing Ehrlich solid carcinoma. Exp Oncol 2017; 39 (1): 42–8.
Hoption Cann SA, van Netten JP, van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 2003; 79 (938): 672–80.
Palomba ML, Roberts WK, Dao T, et al. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. Clin Cancer Res 2005; 11 (1): 370–9.
Hale DF, Clifton GT, Sears AK, et al. Cancer vaccines: should we be targeting patients with less aggressive disease? Expert Rev Vaccines 2012; 11: 721–31.
Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res 2015; 75 (1): 5–10.
Martín-Fontecha A, Thomsen LL, Brett S, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(h)1 priming. Nat Immunol 2004; 5 (12): 1260–5.
Zingoni A, Sornasse T, Cocks BG, et al. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J Immunol 2004; 173: 3716–24.
Senju H, Kumagai A, Nakamura Y, et al. Effect of IL-18 on the expansion and phenotype of human natural killer cells: application to cancer immunotherapy. Int J Biol Sci 2018; 14: 331–40.
Smyth MJ, Swann J, Kelly JM, et al. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med 2004; 200: 1325–35.
Symchych TV, Fedosova NI, Karaman ОМ, et al. The effects of early postoperative immunization with xenogeneic embryo proteins on Lewis lung carcinoma model. Exp Oncol 2018; 40 (4): 275–81.
Seth R, Tai LH, Falls T, et al. Surgical stress promotes the development of cancer metastases by a coagulation-dependent mechanism involving natural killer cells in a murine model. Ann Surg 2013; 258 (1): 158–68.
Tai LH, de Souza CT, Bélanger S, et al. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res 2013; 73 (1): 97–107.
Tai L-H, Auer R. Attacking postoperative metastases using perioperative oncolytic viruses and viral vaccines. Front Oncol 2014; 4: 217 https://www.frontiersin.org/articles/10.3389/fonc.2014.00217/full
Park CG, Hartl CA, Schmid D, et al. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci Transl Med 2018; 10 (433): eaar1916.
Carter JJ, Feingold DL, Oh A, et al. Perioperative immunomodulation with Flt3 kinase ligand or a whole tumor cell vaccine is associated with a reduction in lung metastasis formation after laparotomy in mice. Surg Innov 2006; 13: 41–7.
Symchych TV, Karaman OM, Fedosova NI, et al. Immunization with xenogeneic embryo proteins positively effects macrophages functions in mice bearing Ehrlich carcinoma. Oncology 2019; 21 (1): 81.
Li X, Liu R, Su X, et al. Harnessing tumor-associated macrophages as aids for cancer immunotherapy. Mol Cancer 2019; 18 (1): 177.
Bowen WS, Svrivastava AK, Batra L, et al. Current challenges for cancer vaccine adjuvant development. Expert Rev Vaccines 2018; 17 (3): 207–15.
Kawai K, Miyazaki J, Joraku A, et al. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci 2013; 104 (1): 22–7.
Hu B, Wang J, Guo Y, et al. Pre-clinical toxicity and immunogenicity evaluation of a MUC1-MBP/BCG anti-tumor vaccine. Int Immunopharmacol 2016; 33: 108–18.
Yuan S, Shi C, Liu L, Han W. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy. Expert Opin Biol Ther 2010; 10 (7): 1037–48.
Podaza E, Carri I, Aris M, et al. Evaluation of T-Cell responses against shared melanoma associated antigens and predicted neoantigens in cutaneous melanoma patients treated with the CSF-470 allogeneic cell vaccine plus BCG and GM-CSF. Front Immunol 2020; 11: 1147.
Symchych T, Didkivska L, Karaman O, et al. Antitumor activity of xenogenic embryonic proteins and the BCG immunoаdjuvant. Clin oncol 2011; (II): 224.
